-- InSilico Medicine (HKG:3696) said its investigational new drug application for an inhaled formulation of Rentosertib has been approved by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
The company said the drug is intended for the treatment of idiopathic pulmonary fibrosis.
The approval supports a Phase 1 clinical study to evaluate safety, tolerability, and pharmacokinetics, the filing said.
New Zealand's first-quarter unemployment rate is expected to remain steady at 5.4%, slightly lower than the previous forecast of 5.5%, according to a report by ANZ released on Wednesday.ANZ increased its quarterly employment growth forecast by 0.1 percentage points to 0.3%, with employment growth appearing to have held onto a little more momentum in March than previously anticipated, the report said.Upcoming data on hours paid and hours worked may indicate some signal around the risks to the first-quarter GDP forecast of 0.8% quarter on quarter, though the recent oil shock likely won't show up yet since the labor market is typically the last sector to react to changing economic conditions.First-quarter labor market data is expected to show that the market had enough excess capacity to act as a buffer against the recent oil shock, limiting the risk of labor costs driving up inflation in the near term.
India's production growth, measured by the Index of Industrial Production, slowed to 4.1% in March from 5.2% in February, according to data released by the Ministry of Statistics and Programme Implementation (MoSPI) on Tuesday.In March 2025, India's IIP growth rate was at 3.9%.The quick estimates of IIP came in at 173.2 in March, up from 166.3 in the same month in 2025.The manufacturing sector, which carries the largest weight in the index, grew at 4.3% in March from 4.0% a year earlier. It was, however, lower than the 5.9% growth in February.Mining output grew 5.5% in March against 1.2% in the corresponding period of the previous year. Electricity production, however, fell to 0.8%, compared with 7.5% in the year-ago period.The indices of industrial production for the mining, manufacturing, and electricity sectors for March stood at 166.8, 169.4, and 221.3, respectively.
Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.The company's shares rose 2% in recent Wednesday trade.